This is a routine shelf registration with no immediate capital raise. Monitor for future prospectus supplements that would disclose actual offering terms, size, and use of proceeds. The company's clinical-stage biotech profile and existing short interest (~15.8%) suggest any future equity offering could face above-average dilution sensitivity.
Price Chart
Executive Summary
Tyra Biosciences filed an automatic shelf registration statement (S-3ASR) on September 14, 2026, registering an unspecified amount of common stock, preferred stock, debt securities, warrants, and units for potential future sale. The filing is a standard shelf registration by a well-known seasoned issuer (WKSI), allowing the company to access capital markets opportunistically. No specific offering size, pricing, or immediate dilution is disclosed, making this a routine capital-markets housekeeping filing with no immediate trading impact.
Key Facts
- Tyra Biosciences filed an automatic shelf registration statement (S-3ASR) on September 14, 2026.
- The registration covers an unspecified amount of common stock, preferred stock, debt securities, warrants, and units.
- The filing fee is deferred under Rules 456(b) and 457(r), with no registration fee paid at this time.
- The company is a well-known seasoned issuer (WKSI) as defined in Rule 405 under the Securities Act.
- No specific offering size, price, or terms are disclosed in the filing.
- The company's common stock closed at $22.03 per share on September 11, 2026, with a market cap of $1.3B.
- The company has a history of 3 offering/registration filings in the last 24 months, including this one.
- Short interest is 9.4M shares (~15.8% of estimated shares outstanding) as of August 31, 2026.
Financial Impact
No specific offering size or dollar amount disclosed; registration fee deferred. Potential future dilution is unspecified.
Risk Factors
- Potential future equity dilution from unspecified shelf takedowns.
- Clinical-stage biotech with no approved products; capital needs may necessitate future offerings.
- Elevated short interest (~15.8%) could amplify price moves on any future offering announcement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001193125-26-389752 |
| Document: d49930ds3asr.htm | 0001193125-26-389752 |
| Document: d49930dexfilingfees.htm | 0001193125-26-389752 |
| Document: d49930dex51.htm | 0001193125-26-389752 |
| Document: d49930dex231.htm | 0001193125-26-389752 |
| Document: 0001193125-26-389752-index-headers.html | 0001193125-26-389752 |
| Document: 0001193125-26-389752-index.html | 0001193125-26-389752 |
| Document: 0001193125-26-389752.txt | 0001193125-26-389752 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | S-3ASR | $25.07 $25.65 | ▲ +2.31% | ▲ +2.21% | $20.50 (−18.21%) |
Sep 9, 2026 23d ago | 8-K | $22.01 $24.35 | ▲ +10.63% | ▲ +11.73% | $20.50 (−6.84%) |
Aug 4, 2026 8w ago | 424B5 | $25.71 $25.30 | ▲ +1.59% | ▲ +1.95% | $20.50 (+20.25%) |
Jun 26, 2026 13w ago | 144 | $32.11 $30.86 | ▲ +3.89% | ▲ +5.28% | $20.50 (+36.14%) |
May 13, 2026 20w ago | 8-K | $36.19 $33.78 | ▼ −6.66% | ▼ −5.50% | $20.50 (−43.34%) |
Apr 20, 2026 23w ago | 3 | $36.69 $35.06 | ▼ −4.44% | ▼ −5.53% | $20.50 (−44.11%) |
Apr 17, 2026 24w ago | DEFA14A | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 17, 2026 24w ago | 8-K | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 13, 2026 24w ago | 144 | $35.27 $36.69 | ▲ +4.03% | ▲ +2.63% | $20.50 (−41.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access